{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:10:00Z","timestamp":1760235000531,"version":"build-2065373602"},"reference-count":17,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: The Pfizer-BioNTech (BNT162b2) COVID-19 mRNA vaccine has demonstrated excellent efficacy and safety in phase 3 trials. However, no dialyzed patients were included, and therefore safety data for this patient group is lacking. The aim of the study was to assess the safety and tolerances of vaccinations with BNT162b2 performed in chronically dialyzed patients. Materials and Methods: We performed a prospective cohort study including a group of 190 dialyzed patients (65% male) at median age 68.0 (55\u201374) years. 169 (89.0%) patients were treated with hemodialysis and 21 (11.0%) with peritoneal dialysis. The control group consisted of 160 people (61% male) without chronic kidney disease at median age 63 (range 53\u201377) years. Both groups were vaccinated with BNT162b2 with a 21-day interval between the first and the second dose. Solicited local and systemic reactogenicity, unsolicited adverse events and antipyretic and pain medication use were assessed with a standardized questionnaire. The toxicity grading scales were derived from the FDA Center for Biologics Evaluation and Research guidelines. Results: 59.8% (dose 1), 61.4% (dose 2) and 15.9% (dose 1), 29.4% (dose 2) dialyzed patients reported at least one local and one systemic reaction respectively within seven days after the vaccination. Many local and systemic solicited reactions were observed less frequently in dialyzed patients than in the age and sex matched control group and much less frequently than reported in the pivotal study. They were mostly mild to moderate, short-lived, and more frequently reported in younger individuals and women. No related unsolicited adverse events were observed. Conclusions: We have shown here that BNT162b2, an mRNA vaccine from Pfizer-BioNTech against SARS-COV-2 is safe and well-tolerated by dialyzed patients. The results can be useful for the nephrological community to resolve patients\u2019 doubts and reduce their vaccine hesitancy.<\/jats:p>","DOI":"10.3390\/medicina57070732","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T10:07:37Z","timestamp":1626689257000},"page":"732","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Safety and Tolerability of the BNT162b2 mRNA COVID-19 Vaccine in Dialyzed Patients. COViNEPH Project"],"prefix":"10.3390","volume":"57","author":[{"given":"Karolina","family":"Polewska","sequence":"first","affiliation":[{"name":"Department of Nephrology Transplantology and Internal Medicine, Medical University of Gdansk, 80-210 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Tylicki","sequence":"additional","affiliation":[{"name":"Department of Nephrology Transplantology and Internal Medicine, Medical University of Gdansk, 80-210 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan","family":"Biedunkiewicz","sequence":"additional","affiliation":[{"name":"Department of Nephrology Transplantology and Internal Medicine, Medical University of Gdansk, 80-210 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Ruci\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Occupational, Metabolic and Internal Diseases, Medical University of Gdansk, 80-210 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Szyd\u0142owska","sequence":"additional","affiliation":[{"name":"Department of Occupational, Metabolic and Internal Diseases, Medical University of Gdansk, 80-210 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicja","family":"Kubanek","sequence":"additional","affiliation":[{"name":"Department of Occupational, Metabolic and Internal Diseases, Medical University of Gdansk, 80-210 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwona","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"NZOZ Diaverum, 81-519 Gdynia, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylwia","family":"Rodak","sequence":"additional","affiliation":[{"name":"NZOZ Diaverum, 81-519 Gdynia, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waldemar","family":"\u015alizie\u0144","sequence":"additional","affiliation":[{"name":"NZOZ Diaverum, 81-519 Gdynia, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Renke","sequence":"additional","affiliation":[{"name":"Department of Occupational, Metabolic and Internal Diseases, Medical University of Gdansk, 80-210 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8210-8063","authenticated-orcid":false,"given":"Alicja","family":"D\u0119bska-\u015alizie\u0144","sequence":"additional","affiliation":[{"name":"Department of Nephrology Transplantology and Internal Medicine, Medical University of Gdansk, 80-210 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5515-5072","authenticated-orcid":false,"given":"Leszek","family":"Tylicki","sequence":"additional","affiliation":[{"name":"Department of Nephrology Transplantology and Internal Medicine, Medical University of Gdansk, 80-210 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.kint.2021.02.003","article-title":"The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: A call to action","volume":"99","author":"Francis","year":"2021","journal-title":"Kidney Int."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Puchalska-Regli\u0144ska, E., D\u0119bska-Slizie\u0144, A., Biedunkiewicz, B., Tylicki, P., Polewska, K., Rutkowski, B., Gellert, R., and Tylicki, L. (2021). Extremely high mortality in COVID-19 hemodialyzed patients before the anti-SARS-CoV-2 vaccination era. Large database from the North of Poland. Pol. Arch. Intern. Med.","DOI":"10.20452\/pamw.16028"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Sallam, M. (2021). COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates. Vaccines, 9.","DOI":"10.1101\/2020.12.28.20248950"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Garcia, P., Montez-Rath, M.E., Moore, H., Flotte, J., Fults, C., Block, M.S., Han, J., Dittrich, M., Parsonnet, J., and Chertow, G.M. (2021). SARS-CoV-2 Vaccine Acceptability in Patients on Hemodialysis: A Nationwide Survey. J. Am. Soc. Nephrol.","DOI":"10.1681\/ASN.2021010104"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1681\/ASN.2020121766","article-title":"COVID-19 and Dialysis Patients: Unsolved Problems in Early 2021","volume":"32","author":"Kliger","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1016\/j.vaccine.2013.08.087","article-title":"Assessment of causality of individual adverse events following immunization (AEFI): A who tool for global use","volume":"31","author":"Tozzi","year":"2013","journal-title":"Vaccine"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Chapin-Bardales, J., Gee, J., and Myers, T. (2021). Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines. JAMA.","DOI":"10.1001\/jama.2021.5374"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Menni, C., Klaser, K., May, A., Polidori, L., Capdevila, J., Louca, P., Sudre, C.H., Nguyen, L.H., Drew, D.A., and Merino, J. (2021). Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study. Lancet Infect. Dis.","DOI":"10.1016\/S1473-3099(21)00224-3"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1525-139X.2007.00283.x","article-title":"Disturbances of acquired immunity in hemodialysis patients","volume":"20","author":"Eleftheriadis","year":"2007","journal-title":"Semin. Dial."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/ageing\/afaa274","article-title":"Efficacy and safety of COVID-19 vaccines in older people","volume":"50","author":"Soiza","year":"2021","journal-title":"Age Ageing"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2215\/CJN.03500321","article-title":"Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis","volume":"16","author":"Grupper","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.15585\/mmwr.mm7008e3","article-title":"First Month of COVID-19 Vaccine Safety Monitoring\u2014United States, December 14, 2020\u2013January 13, 2021","volume":"70","author":"Gee","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Tylicki, L., Biedunkiewicz, B., D\u0105browska, M., \u015alizie\u0144, W., Tylicki, P., Polewska, K., Rosenberg, I., Rodak, S., and D\u0119bska-\u015alizie\u0144, A. (2021). Humoral response to SARS-CoV-2 vaccination promises to improve the catastrophic prognosis of hemodialysis patients as a result of COVID-19. The COViNEPH Project. Pol. Arch. Inern. Med., accepted.","DOI":"10.20452\/pamw.16069"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how\u2019s and what\u2019s of vaccine reactogenicity","volume":"4","author":"Herve","year":"2019","journal-title":"NPJ Vaccines"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.2215\/CJN.00950208","article-title":"Aspects of immune dysfunction in end-stage renal disease","volume":"3","author":"Kato","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_17","unstructured":"Rana, K., Mohindra, R., and Pinnaka, L. (2021). Vaccine breakthrough infections with sars-cov-2 variants. N. Engl. J. Med."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/7\/732\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:31:55Z","timestamp":1760164315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/7\/732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,19]]},"references-count":17,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["medicina57070732"],"URL":"https:\/\/doi.org\/10.3390\/medicina57070732","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2021,7,19]]}}}